

**APA063Hu01 100µg**

**Active Interleukin 17 (IL17)**

**Organism Species: Homo sapiens (Human)**

***Instruction manual***

FOR IN VITRO USE AND RESEARCH USE ONLY  
NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES

---

---

1st Edition (Apr, 2016)

## **[ PROPERTIES ]**

**Source:** Prokaryotic expression.

**Host:** *E. coli*

**Residues:** Ile20~Ala155

**Tags:** N-terminal His-tag

**Purity:** >98%

**Buffer Formulation:** 20mM Tris, 150mM NaCl, pH8.0, containing 0.05% sarcosyl and 5% trehalose.

**Applications:** Cell culture; Activity Assays; In vivo assays.

(May be suitable for use in other assays to be determined by the end user.)

**Predicted isoelectric point:** 9.0

**Predicted Molecular Mass:** 19.5kDa

**Accurate Molecular Mass:** 20kDa as determined by SDS-PAGE reducing conditions.

## **[ USAGE ]**

Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

## **[ STORAGE AND STABILITY ]**

**Storage:** Avoid repeated freeze/thaw cycles.

Store at 2-8°C for one month.

Aliquot and store at -80°C for 12 months.

**Stability Test:** The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

## **[ SEQUENCE ]**

```
          I VKAGITIPRN  PGCPNSEDKN  FPRTVMVNLN  
IHNRRNTNTNP  KRSSDYYNRS  TSPWNLHRNE  DPERYPSVIW  EAKCRHLGCI  
NADGNVDYHM  NSVPIQQEIL  VLRREPPHCP  NSFRLEKILV  SVGCTCVTPI  
VHHVA
```

## **[ ACTIVITY ]**

IL17 (interleukin 17) is a member of IL17 cytokine family, which is a proinflammatory cytokine produced by activated T cells. This cytokine regulates the activities of NF-kappaB and mitogen-activated protein kinases. It is reported that IL17 is a ligand for IL17RA, indicating its interaction with IL17RA. Thus, a binding ELISA assay was constructed to detect the association of recombinant human IL17 with recombinant human IL17RA. Briefly, IL17 were diluted serially in PBS with 0.1%BSA (pH 7.4). Duplicate samples of 100uL were then transferred to IL17RA-coated microtiter wells and incubated for 2h at 37°C. Wells were washed with PBST and incubated for 1h with anti-IL17 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution , wells were incubated 15-25 minutes at 37°C. Finally, add 50µL stop solution to the wells and read at 450nm immediately. The binding activity of IL17 with IL17RA was shown in Figure 1 and this effect was in a dose dependent manner.




Figure 1. The binding activity of IL17 with IL17RA.

## [ IDENTIFICATION ]





Figure 2. SDS-PAGE

Sample: Active recombinant IL17, Human



**Figure 3. Western Blot**

**Sample: Recombinant IL17, Human;**

**Antibody: Rabbit Anti-Human IL17 Ab (PAA063Hu01)**